Arcturus Therapeutics Holdings Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Arcturus Therapeutics Holdings Inc. (ARCT) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Operating Activities
Net Income-80.94-29.739.35-203.67-72.15-25.99
Depreciation & Amortization3.542.961.531.190.880.68
Stock Based Compensation37.9934.6530.6128.926.760.00
Change in Working Capital-20.817.65-11.3432.6321.2215.98
Change in Accounts Receivable28.09-29.300.60-1.240.050.00
Change in Accounts Payable1.92-2.24-3.11-0.774.810.00
Change in Other Working Capital-50.810.314.651.849.310.00
Other Operating Activities0.4734.8931.571.410.162.88
Net Cash from Operating Activities-59.75-18.1031.99-135.04-42.86-6.45
Investing Activities
Capital Expenditures-0.652.907.73-3.41-1.740.82
Net Cash from Investing Activities-0.65-2.90-7.73-3.41-1.74-0.82
Financing Activities
Debt Repayment0.00-47.36-5.000.000.000.00
Common Stock Issued0.680.610.411.42436.1521.28
Other Financing Activities4.740.000.000.000.000.00
Net Cash from Financing Activities5.42-24.09-2.8648.02436.1526.36
Summary
Net Change in Cash-54.98-45.0921.41-90.43391.5419.10
Cash at Beginning of Period348.89393.98372.57463.0071.4636.82
Cash at End of Period293.912.28393.98372.57453.4055.92
Free Cash Flow-60.40-21.0024.27-138.45-44.60-7.26
Supplemental Disclosures
Interest Paid0.002.130.810.680.750.69
Income Taxes Paid1.410.000.000.000.000.00